福建海西新藥創制股份有限公司 公司董事會薪酬與考核委員會職權範圍 第一章 總 則 第一條 為進一步健全福建海西新藥創制股份有限公司（以 下 簡 稱「公 司」）董 事 及 高 級 管 理 人 員 的 薪 酬 管 理 制 度，完 善 考 核 和 評 價 體 系，根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公 司 法》」）、《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下簡稱「《上 市 規 則》」）、《上 市 規 則》附 錄C1所 載《企 業 管 治 守 則》、公 司 的《公 司 章 程》（以 下 簡 稱「《公 司 章 程》」）及 其 他 有 關 適 用 法 律 法 規 以 及 監 管 文 件，特 設 立 本 公司董事會（以 下 簡 稱「董事會」）薪酬與考核委員會（以 下 簡 稱「薪酬與考核委員 會」），並 制 定 本 職 權 範 圍。 第二條 薪酬與考核委員會是董事會根據《公 司 章 程》設 立 的 專 門 工 作 機 構，主 要 負 責 研 究 並 制 定 公 司 董 事、高 級 管 理 人 員 的 考 核 標 準 及 考 核 辦 法，進 行 考 核 並 提 ...

| | 3 | 第一章 | 總則 | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 4 | 第二章 | 經營宗旨和範圍 | | | | | | | | | | | | | | | | | 5 | 第三章 | 股份 | | | | | | | | | | | | | | | | 股東和股東會 | 11 | 第四章 | | | | | | | | | | | | | | | | | 董事會 | 32 | 第五章 | | | | | | | | | | | | | | | | | 董事會秘書 | 43 | 第六章 | | | | | | | | | | | | | | | | | 總經理和其他高級管理人員 | 44 | 第七章 | | | | | | | | | | | | | | | | | 監事會 | 46 | 第八章 | | | | | | | | | | | | | | | ...

第四條 審 核 委 員 會 須 全 部 由 非 執 行 董 事 組 成，大 部 分 委 員 須 為 獨 立 非 執 行 董 事，其 中 至 少 包 括 一 名 具 備 相 關 法 律 法 規 和《上 市 規 則》的 適 當 專 業 資 格，或 具 備 適 當 的 會 計 或 相 關 財 務 管 理 專 長 的 獨 立 非 執 行 董 事。 福建海西新藥創制股份有限公司 公司董事會審核委員會職權範圍 第一章 總 則 第一條 為監督福建海西新藥創制股份有限公司（以 下 簡 稱「公 司」）的會計和財 務 匯 報 程 序 以 及 公 司 財 務 報 表 的 審 核 工 作，根 據《中 華 人 民 共 和 國 公 司 法》（以 下簡稱「《公 司 法》」）、香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（以 下 簡 稱「《上 市 規 則》」）、《上 市 規 則》附 錄C1所 載《企 業 管 治 守 則》、公 司 的《公 司 章 程》（以 下 簡 稱 「《公 司 章 程》」）及 其 他 有 關 適 用 法 律、法 規 及 監 管 規 定，特 設 公 司 董 事 會（以 下 簡 稱「董事會」）審核委員會（ ...

| 141.971 | 64.32% | | | | --- | --- | --- | --- | | | | 十档 | 成交明细 | | | | 109.200 | | | | | 109.100 | - - (- -) | | | | 109.000 | - -(- -) | | | | 108.900 | - -(- -) | | | | 108.800 | - -(- -) | | | | 108.700 | - -(- -) | | | | 108.600 | - -(- -) | | | | 108.500 | - - (- -) | | 86.400 | | 108.400 | - - (- -) | | | | 108.300 | 100(2家) | | | | 108.100 | 250(3家) | | | | 108.000 | 2100(7家) | | | | 107.900 | 50(1家) | | | | 107.800 | 1300(1家) | | | | 107.700 | 550(2家) | | | | 107.600 | | 智通财经APP获悉，海西新药(02637)将于1 ...

Core Viewpoint - HaiXi Pharmaceutical (02637) is set to list on the Hong Kong Stock Exchange on October 17, with pre-listing trading indicating a significant price increase from the initial offering price [1]. Group 1: Listing Details - HaiXi Pharmaceutical will officially list on October 17, 2023 [1]. - The initial offering price was set at HKD 86.4, while the dark trading price is currently at HKD 130.9, reflecting a 51.5% increase [1][2]. Group 2: Trading Performance - The dark trading volume reached 61,100 shares, with a highest price of HKD 176.0 and a lowest price of HKD 129.0 [2]. - The total market capitalization of HaiXi Pharmaceutical is approximately HKD 10.303 billion [2]. - The average trading price during the session was HKD 136.275, with a turnover rate of 0.08% [2].

DI 16:15 17:00 17:30 18:00 18:30 分时 1分 5分 日K 买盘十档 卖盘十档 44.35% 55.65% 立即买入 立即卖出 • 行情来源: 利弗莫尔证券 • | > | 海西新药 | | a 0 | | | --- | --- | --- | --- | --- | | 曾页 | HK 02637 暗盘 | | | | | 行情 板块 | 评论 券商持仓 | | 实时数据 股东 | | | 130.900 | 成交量 6.11万股 | 最高 176.000 | 今开 172.000 | | | +51.50% +44.500 | 换手 0.08% | 最低 129,000 | 总市 103.03亿 | | | 20251016 16:17 价 130.900 51.50% 均 136.275 分时量 1.37万股 | | | | | | 141.971 | | 64.32% | 十档 | 成交明细 | | | | | 132.100 | - - (- -) | | | | | 132.000 | - - - - - - - - | | | | | 131.900 | - - ...

Core Viewpoint - HaiXi Pharmaceutical has successfully completed its IPO subscription, raising significant interest with an oversubscription of 3113 times the initial public offering amount, indicating strong market demand for its shares [1] Group 1: IPO Details - HaiXi Pharmaceutical's IPO took place from October 9 to 14, with a total of HKD 3.094 billion in margin loans borrowed by brokers [1] - The company plans to issue 11.5 million H-shares, with a public offering price range between HKD 69.88 and HKD 86.4, aiming to raise up to HKD 990 million [1] - The expected listing date is October 17, with Huatai International and China Merchants Jinling International serving as joint sponsors [1] Group 2: Business Overview - HaiXi Pharmaceutical is a commercial-stage pharmaceutical company engaged in research, development, production, and sales, with a pipeline of innovative drugs under development [1] - The company has a portfolio of generic drugs targeting various diseases, including gastrointestinal, cardiovascular, endocrine, neurological, and inflammatory diseases, with 15 generic drugs approved by the National Medical Products Administration [1] - Four of these generic drugs are included in the national volume-based procurement (VBP) program [1] Group 3: Innovative Drug Pipeline - The company's innovative drug pipeline includes a novel oncology drug and an oral medication for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [2] - The fastest progressing drug in the pipeline is C019199, targeting osteosarcoma, which is set to enter Phase III trials in the second half of this year [2] Group 4: Financial Performance - The company's projected revenues for 2022, 2023, 2024, and the five months ending May 31, 2025, are RMB 212.5 million, RMB 316.6 million, RMB 466.7 million, and RMB 249.2 million, respectively [2] - Corresponding gross profits for the same periods are RMB 172.1 million, RMB 263.6 million, RMB 387.2 million, and RMB 209.3 million [2] Group 5: Use of Proceeds - Approximately 52% of the net proceeds from the fundraising will be allocated to ongoing research and development to advance the drug pipeline [3] - 23% will be used to enhance R&D capabilities and seek collaboration opportunities, while 8% will focus on improving commercialization capabilities and expanding market influence [3] - Additional allocations include 7% for optimizing R&D and production systems, and 10% for working capital and other general corporate purposes [3]

Core Viewpoint - HaiXi Pharmaceutical (02637) has successfully completed its IPO subscription, raising significant interest with an oversubscription of 3113 times the initial public offering amount of HKD 993.6 million [1] Group 1: IPO Details - The company raised HKD 309.4 billion in margin financing from brokers during the subscription period from October 9 to 14 [1] - HaiXi Pharmaceutical plans to issue 11.5 million H-shares, with 10% allocated for public offering at a price range of HKD 69.88 to HKD 86.4 per share [1] - The expected listing date is October 17, with Huatai International and CMB International serving as joint sponsors [1] Group 2: Business Overview - HaiXi Pharmaceutical is a commercial-stage pharmaceutical company engaged in research, development, production, and sales, with a pipeline of innovative drugs under development [1] - The company has a portfolio of generic drugs targeting various diseases, including gastrointestinal, cardiovascular, endocrine, neurological, and inflammatory diseases, with 15 generic drugs approved by the National Medical Products Administration [1] - Four of these generic drugs are included in the national volume-based procurement (VBP) program [1] Group 3: Innovative Drug Pipeline - The innovative drug pipeline includes a cancer drug, an oral medication for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), along with two other drugs in preclinical stages for cancer and respiratory diseases [2] - The most advanced drug, C019199 for osteosarcoma, is set to enter Phase III trials in the second half of this year [2] Group 4: Financial Projections - The company's projected revenues for 2022, 2023, 2024, and the five months ending May 31, 2025, are RMB 212.5 million, RMB 316.6 million, RMB 466.7 million, and RMB 249.2 million, respectively [2] - Corresponding gross profits are projected to be RMB 172.1 million, RMB 263.6 million, RMB 387.2 million, and RMB 209.3 million for the same periods [2] Group 5: Use of Proceeds - Approximately 52% of the net proceeds from the fundraising will be allocated to ongoing research and development to advance the drug pipeline [3] - 23% will enhance research capabilities and seek collaboration opportunities, while 8% will improve commercialization capabilities and expand market influence [3] - The remaining funds will be used for optimizing research and production systems (7%) and for working capital and other general corporate purposes (10%) [3]

Industry Dynamics - Nvidia is hosting the 2025 Global Summit on Open Computing, and Oracle is unveiling its AI World Conference [7] - The 138th Canton Fair will be held in three phases in Guangzhou [7] - A revised Anti-Unfair Competition Law will take effect on October 15, enhancing fair competition rules in the digital economy [7] - TSMC is set to announce its earnings [8] - The 2025 World Intelligent Connected Vehicles Conference will take place in Beijing [8] Company News - Xuan Bamboo Biotechnology-B (02575.HK) is set to be listed on October 15 [9] - Yunji (02670.HK) will be listed on October 16, along with earnings announcements from China Tower and Fuyao Glass [10] - Zijin Mining will release its earnings on October 17, and Haixi New Drug (02637.HK) will be listed [11]

公司拟将所得款项净额中，约52%用于持续投资于研发，以推进管线中的在研药物并丰富产品组合；约 23%用于提升研发能力及寻求合作机会；约8%用于增强商业化能力及扩大市场影响力；约7%用于改善 及优化研发和生产系统；及约10%用作营运资金及其他一般企业用途。 来源：格隆汇APP 格隆汇10月9日｜中国制药公司海西新药(2637.HK)今日起至下周二(10月14日)招股，发售1150万股H 股，香港公开发售占10%，其余为国际配售，每股招股价介乎69.88港元至86.4港元，集资最多9.94亿港 元。一手50股，入场费4363.57港元。该股预期10月17日挂牌买卖。华泰国际及招银国际为联席保荐 人。 ...